Group 1 | Group 2 | Group 3 | ANOVA analysis between groups | |
---|---|---|---|---|
First year treatment | EO | GH | GH&EO | |
Subsequent treatment | GH&EO | GH1-150 | GH&EO | |
Number | 13 | 22 | 23 | |
Age (y) | 9.1 (6.0 to 13.7) | 9.0 (5.2 to 15.4) | 9.1 (5.0 to 14.7) | NS |
Bone age (y) | 7.9 (3.0 to 13.7) | 8.0 (3.3 to 13.5) | 8.1 (3.0 to 12.9) | NS |
Height (cm) | 114.0 (94.6 to 140.0) | 113.2 (93.2 to 135.1) | 114.9 (93.6 to 139.2) | |
HSDS for CA | −0.1 (−1.5 to +1.8 ) | −0.3 (−2.1 to +1.2 ) | 0.1 (−2.2 to +1.8 ) | NS |
HSDS for BA | 1.0 (−0.6 to +2.4 ) | 0.6 (−0.8 to +3.3 ) | 0.8 (−1.6 to +2.7) | NS |
GH peak (mIU/l) | 27.8 (9.5 to 44.0) | 27.0 (7.9 to 81.0) | 22.3 (2.8 to 60.0) | NS |
Mid parental HSDS | −0.3 (1.1) | −0.2 (0.8) | 0.7 (1.1) | NS |
Results expressed as mean (range) or (SD).
↵1-150 Oestrogen introduced after age 12 years.
EO, ethinyloestradiol; GH, growth hormone; GH&EO, combined treatment; CA, chronological age; BA, bone age; HSDS, height standard deviation score; NS, not significant.